The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Road to Clinical Efficacy: Challenges and Novel Strategies for Antimicrobial Peptide Development
Abstract
Since the discovery of magainins, cecropins and defensins 30 years ago, antimicrobial peptides (AMPs) have been hailed as a potential solution to the dearth of novel antibiotic development. AMPs have shown robust activity against a wide variety of pathogens, including drug-resistant bacteria. Unlike small-molecule antibiotics, however, AMPs have failed to translate this success to the clinic. Only the polymyxins, gramicidins, nisin and daptomycin are currently approved for medical use; the latter is the only example to have been developed in the last several decades. Nonetheless, researchers continue to isolate, modify and develop novel AMPs for therapeutic applications. Efforts have focused on increasing stability, reducing cytotoxicity, improving antimicrobial activity and incorporating AMPs in novel formulations, including nanoscale particles. As peptide synthesis and recombinant production methodologies improve, and more relevant bioassays become available, it becomes increasingly likely that AMPs will break the regulatory barrier and enter the marketplace as valuable antimicrobial weapons in the next 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
Espinel-Ingroff, A. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70004-x · Cited by 105
Cited by
Chemically modified and conjugated antimicrobial peptides against superbugs
Li, W., Separovic, F., O'Brien-Simpson, N. M., & Wade, J. D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01026j · Cited by 439
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
Carlet, J., Jarlier, V., Harbarth, S., Voss, A., Goossens, H., Pittet, D., & Forum, T. P. O. T. 3. W. H.-A. I. (2012) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-1-11 · Cited by 350
LAMP: A Database Linking Antimicrobial Peptides
Zhao, X., Wu, H., Lu, H., Li, G., & Huang, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066557 · Cited by 346
Antimicrobial Peptides: An Update on Classifications and Databases
Bin Hafeez, A., Jiang, X., Bergen, P. J., & Zhu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111691 · Cited by 341
Ong, Z. Y., Wiradharma, N., & Yang, Y. Y. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.013 · Cited by 313
Metadata
- Authors
- Eckert, R.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2011-06
- Volume
- 6
- Issue
- 6
- Pages
- 635-651
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2118899980
- Cited by
- 204
- References
- 3
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Road to Clinical Efficacy: Challenges and Novel Strategies for Antimicrobial Peptide Development. https://app.cochat.ai/papers/10.2217/fmb.11.27
- The paper
- Eckert, R. (2011). Road to Clinical Efficacy: Challenges and Novel Strategies for Antimicrobial Peptide Development. Future Microbiology. https://doi.org/10.2217/fmb.11.27
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.